Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Drug delivery can play an important role at all stages of a drug's lifecycle and has become an ever present feature in the business model of the leading pharmaceutical companies. Using the PharmaVitae Explorer database, the report provides an in depth sales analysis of the specific routes of administration driving the pharmaceutical market out to 2014.

Pharmaceutical Licensing Overview - Risk-aversion breeds creativity as externalization intensifies

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic.

Pharmaceutical Key Trends 2010 - The patent cliff dominates but growth opportunities remain

Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 2010/14 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

U.S. Preterm Infant Care Market

Preterm infant care forms a significant part of the pediatric healthcare market in the U.S. as preterm births are one of the leading causes of infant mortality in the country. One in every eight births in the U.S. are preterm, and the condition is on an alarming rise due to factors such as induced fertility, labor treatments, poor prenatal care, inappropriate maternal age, obesity, and smoking.

Sales Vision Road Show Beograd - a great expirience

The first iPhone Pharma CRM application in the world was shown in Belgrade on Sales Vision Road Show, senior management event which gathered more than 50 delegates from pharma world of Serbia, Croatia and Bosnia and Herzegovina. Sales Vision Road Show is going on in other cities across Europe like in London, Bratislava, Bucurest etc.

2010 Pharma CI Conference & Exhibition

September 21-22, 2010

Hilton Parsippany Hotel, New Jersey, USA

Join us at this premier gathering and network with other key decision makers as you learn about the most pressing and relevant issues facing the competitive intelligence community today. This is the only event featuring a world-class line up of speakers and panelists offering their unique insights and expertise on the topics you care about most.

Big pharma struggles to benefit from increased CVD drug usage

London - Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research* by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in 2018. Patent expiries and generic competition will have a major impact and Datamonitor expects AstraZeneca and Novo Nordisk to emerge as the only major CVD pharma companies to generate positive sales growth over the period.

Disease Modification in Rheumatoid Arthritis - Anti-TNFs defend first-line biologic position despite competition

Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017. The sustained uptake of anti-TNFs combined with the launch of several new biologic products will drive growth in the short-and mid-term. However, biosimilar entry will cause a small contraction in market value at the end of the forecast period.

Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market

Drugs with new mechanisms, in particular Pfizer's oral JAK inhibitor CP-690,550 and Chugai/Roche's Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018.

AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty

Having signed a license agreement with AstraZeneca, Rigel has boosted the prospects for R788, its RA drug. However, Phase III trials must address certain safety signals and reassure physicians of its efficacy in key patient populations. Prominent product differentiation will also be vital for the drug to compete with Pfizer's JAK inhibitor, which is set to reach the market two years ahead of it.

Lacerta BioCapital

Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies.

Please contact us for introduction to Lacerta BioCapital. 

Pain Market Overview - Non-traditional analgesics and opioid reformulations to sustain sector growth

The mature pain market has experienced a turbulent 4-year period during which the estimated seven major market sales value has fallen from an all-time high in 2004 down to $24.29 billion in 2007. However, through the growing use of non-traditional analgesics and the emergence of a number of opioid reformulations, the market is set to consolidate in a new phase of growth and prosperity.

The Pain Management Market Outlook To 2014: Competitive landscape, pipeline analysis and growth opportunities

This report provides comprehensive coverage of major markets within the global pain management area, incorporating a epidemiological analysis of key neuropathic and nociceptive pain indications and the main factors impacting their prevalence. This report reviews the factors and underlying trends that are shaping the pain management market and identifies areas of potential growth.

Neuropathic Pain - Brighter future for pipeline drugs while current brands downgraded

Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets (US, Japan, and the 5EU [France, Germany, Italy, Spain and the UK]). Although the US will provide the greatest increase in value over this period, Japan and the 5EU markets will post double-digit compound annual growth rates.

New hope for Javelin's pain candidate but safety concerns remain

An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Stakeholder Opinions: Back Pain - Gain competitive edge by targeting subpopulations

Back pain can restrict activity and quality of everyday life and in some cases is a potentially chronic and even crippling condition. Therefore, back pain exerts a large economic impact on society. Due to the high prevalence of back pain, Datamonitor believes that the condition represents a commercially attractive target to pharmaceutical companies with an interest in the pain market.